Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands

Abstract

Dapagliflozin in combination with insulin was estimated to be a cost-effective treatment option for patients with T2DM whose insulin treatment regimen does not provide adequate glycaemic control in a Dutch healthcare setting.

Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin

“…Similarly, in a UK population of patients on metformin, the addition of DAPA was shown to be a cost‐effective treatment option, particularly because of the positive effect on weight loss, compared with the addition of a DPP‐4 inhibitor . DAPA was also found to be cost‐effective, reducing the overall incidence of macrovascular and microvascular complications and increasing life expectancy in patients who added DAPA to insulin compared with those on insulin alone . A recently conducted study in a Swedish population found new users of DAPA had lower hospital costs and a lower risk of all‐cause mortality compared with users of DPP‐4 inhibitors, but similar overall costs ($6042 vs. $6363; P = 0.128).…”

The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus

“…This study aimed to assess the long‐term health economic consequences of dapagliflozin versus sulfonylurea, as an add‐on to metformin, from the perspective of the UK NHS. Assessments of the cost‐effectiveness of dapagliflozin versus other antidiabetes agents used as an add‐on to metformin, and in indications other than an add‐on to metformin and settings other than the UK have been presented elsewhere .…”

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

“…When added to metformin, dapagliflozin was reported to be a cost-effective treatment option compared with dipeptidyl peptidase-4 inhibitors, sulphonylureas or thiazolidinediones in patients inadequately controlled on metformin alone [25,100–102]. Moreover, dapagliflozin in combination with insulin was also estimated to be a cost-effective treatment for patients who failed to get adequate glycaemic control with insulin alone [103]. These studies confirmed the beneficial profile of dapagliflozin for treating T2DM.…”